Endocannabinoid control of food intake and energy balance

  title={Endocannabinoid control of food intake and energy balance},
  author={Vincenzo Di Marzo and Isabelle Matias},
  journal={Nature Neuroscience},
Marijuana and its major psychotropic component, Δ9-tetrahydrocannabinol, stimulate appetite and increase body weight in wasting syndromes, suggesting that the CB1 cannabinoid receptor and its endogenous ligands, the endocannabinoids, are involved in controlling energy balance. The endocannabinoid system controls food intake via both central and peripheral mechanisms, and it may also stimulate lipogenesis and fat accumulation. Here we discuss the multifaceted regulation of energy homeostasis by… 

The endogenous cannabinoid system in the control of food intake and energy balance

The mechanism by which marijuana exerts its pharmacological actions increased considerably following the identification in the early 1990s of the sites of action of Δ9-tetrahydrocannabinol (Δ9-THC), the cannabinoid CB1 and CB2 receptors and, subsequently, of the endocannabinoids.

Endocannabinoids in Energy Homeostasis and Metabolic Disorders

The endocannabinoid system was discovered, and its role in energy homeostasis moved into focus, and the main psychoactive constituent of marihuana, ∆ 9 -THC, was identified.

Endocannabinoid system and its role in energy regulation

Dysregulation of the endocannabinoid system might contribute to the development of eating disorders and explain why CB1 receptor blockers are efficacious at reducing not only food intake but also the metabolic consequences of visceral adiposity and obesity.

Role of the endocannabinoid system in energy balance regulation and obesity.

  • D. Cota
  • Medicine, Biology
    Frontiers of hormone research
  • 2008
Although further investigation is needed to better define the actual mechanisms of action, pharmacologic approaches targeting the ECS may provide a novel, effective option for the management of obesity, type 2 diabetes and cardiovascular disease.

Endocannabinoid signaling and food addiction

Endocannabinoid system overactivity and the metabolic syndrome: Prospects for treatment

Rimonabant, a selective CB1 receptor antagonist, has been shown to promote weight loss, reduce inflammation, improve dyslipidemia, and improve glucose homeostasis.

Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats

This study examined the acute actions of the putative endocannabinoid noladin ether on food intake and eating motivation, assessing how it affects the amount of work expended by animals to obtain food.



Endocannabinoids and the regulation of body fat: the smoke is clearing.

  • T. Horvath
  • Biology, Medicine
    The Journal of clinical investigation
  • 2003
Examination of the underlying mechanisms reveals a dual role for endocannabinoids as they affect both appetite and peripheral lipolysis in CB1-/- mice.

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

It is shown that the lack of CB1 in mice with a disrupted CB1 gene causes hypophagia and leanness, and the cannabinoid system is an essential endogenous regulator of energy homeostasis via central orexigenic as well as peripheral lipogenic mechanisms and might therefore represent a promising target to treat diseases characterized by impaired energy balance.

Trick or treat from food endocannabinoids?

The content of endocannabinoids in foods, and in cocoa in particular, is not sufficient to produce cannabis-like effects in mammals.

Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin

The first demonstration of a functional relationship between brain ghrelin and endocannabinoid systems is demonstrated and, although it needs to be further investigated, the effect of gh Relin on food intake when injected into the PVN seems to be mediated by stimulation of cannabinoid release.

Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa

Findings show for the first time a derangement in the production of the endogenous cannabinoid AEA in drug-free symptomatic women with anorexia nervosa or with binge-eating disorder, which suggests a possible involvement of AEE in the mediation of the rewarding aspects of the aberrant eating behaviors occurring in AN and BED.

Leptin-regulated endocannabinoids are involved in maintaining food intake

It is shown that following temporary food restriction, CB1 receptor knockout mice eat less than their wild-type littermates, and the CB1 antagonist SR141716A reduces food intake in wild- type but not knockout mice, which indicates that endocannabinoids in the hypothalamus may tonically activate CB1 receptors to maintain food intake and form part of the neural circuitry regulated by leptin.

The endocannabinoid system and its therapeutic exploitation

The conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come are explored.

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

It is concluded that anandamide acting at hepatic CB(1) contributes to diet-induced obesity and that the FAS pathway may be a common molecular target for central appetitive and peripheral metabolic regulation.